WallStreetZenWallStreetZen

NASDAQ: IMRN
Immuron Ltd Stock

$2.32+0.02 (+0.87%)
Updated May 17, 2024
IMRN Price
$2.32
Fair Value Price
-$0.13
Market Cap
$13.21M
52 Week Low
$1.48
52 Week High
$5.96
P/E
-5.31x
P/B
1.15x
P/S
4.39x
PEG
N/A
Dividend Yield
N/A
Revenue
$2.34M
Earnings
-$2.64M
Gross Margin
68.8%
Operating Margin
-108.26%
Profit Margin
-108.5%
Debt to Equity
0.13
Operating Cash Flow
-$2M
Beta
0.33
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

IMRN Overview

Immuron Limited, a biopharmaceutical company, researches, develops, and commercializes polyclonal antibodies in Australia, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It markets Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and reduce the symptoms of minor gastro-intestinal disorders, as well as for dietary supplement for digestive tract protection; and Protectyn, an immune supplement to maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) that is in Phase III clinical trials to reduce the risk of contracting travelers' diarrhea, as well as acts as an anti-viral activity against SARS-CoV-2; and IMM-529, which is in clinical development stage focuses on treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and ETEC infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is based in Carlton, Australia.

Zen Score

Industry Average (22)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how IMRN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.

Due Diligence Checks

IMRN ($2.32) is overvalued by 1,872.34% relative to our estimate of its Fair Value price of -$0.13 based on Discounted Cash Flow (DCF) modelling
Below Fair Value Valuation
IMRN ($2.32) is not significantly undervalued (1,872.34%) relative to our estimate of its Fair Value price of -$0.13 based on Discounted Cash Flow (DCF) modelling, when including a healthy margin of safety
Significantly Below Fair Value Valuation
IMRN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more IMRN due diligence checks available for Premium users.

Be the first to know about important IMRN news, forecast changes, insider trades & much more!

IMRN News

Valuation

IMRN fair value

Fair Value of IMRN stock based on Discounted Cash Flow (DCF)
Price
$2.32
Fair Value
-$0.13
Undervalued by
1,872.34%
IMRN ($2.32) is overvalued by... subscribe to Premium to read more.
Below Fair Value Valuation
IMRN ($2.32) is not significantly... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
IMRN is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation

IMRN price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-5.31x
Industry
8.47x
Market
30.97x

IMRN price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
1.15x
Industry
6.01x
IMRN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation

IMRN's financial health

Profit margin

Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
IMRN's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
IMRN's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials

Assets to liabilities

Assets
$13.5M
Liabilities
$1.6M
Debt to equity
0.13
IMRN's short-term assets ($12.38M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
IMRN's short-term assets ($12.38M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
IMRN's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
IMRN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials

Cash flow

Operating
N/A
Investing
N/A
Financing
N/A
IMRN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials

IMRN vs Biotech Stocks

TickerMarket Cap1d %P/EP/B
IMRN$13.21M+0.87%-5.31x1.15x
IMNN$13.16M0.00%-0.69x1.55x
COEP$12.99M-1.41%-0.65x2.98x
ELAB$12.94M+5.38%-1.86x5.20x
DOMH$12.83M+2.39%-0.46x0.27x

Immuron Stock FAQ

What is Immuron's quote symbol?

(NASDAQ: IMRN) Immuron trades on the NASDAQ under the ticker symbol IMRN. Immuron stock quotes can also be displayed as NASDAQ: IMRN.

If you're new to stock investing, here's how to buy Immuron stock.

What is the 52 week high and low for Immuron (NASDAQ: IMRN)?

(NASDAQ: IMRN) Immuron's 52-week high was $5.96, and its 52-week low was $1.48. It is currently -61.07% from its 52-week high and 56.65% from its 52-week low.

How much is Immuron stock worth today?

(NASDAQ: IMRN) Immuron currently has 227,798,346 outstanding shares. With Immuron stock trading at $2.32 per share, the total value of Immuron stock (market capitalization) is $13.21M.

Immuron stock was originally listed at a price of $8.36 in Jun 9, 2017. If you had invested in Immuron stock at $8.36, your return over the last 6 years would have been -72.23%, for an annualized return of -19.23% (not including any dividends or dividend reinvestments).

How much is Immuron's stock price per share?

(NASDAQ: IMRN) Immuron stock price per share is $2.32 today (as of May 17, 2024).

What is Immuron's Market Cap?

(NASDAQ: IMRN) Immuron's market cap is $13.21M, as of May 20, 2024.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

Immuron's market cap is calculated by multiplying IMRN's current stock price of $2.32 by IMRN's total outstanding shares of 227,798,346.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.